Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma | Zendy

Thomas Powles | Zendy; Peter H. O’Donnell | Zendy; Christophe Massard | Zendy; Hendrik-Tobias Arkenau | Zendy; Terence W. Friedlander | Zendy; Christopher Hoimes | Zendy; JaeLyun Lee | Zendy; Michael Ong | Zendy; Srikala S. Sridhar | Zendy; Nicholas J. Vogelzang | Zendy; Mayer Fishman | Zendy; Jingsong Zhang | Zendy; Sandy Srinivas | Zendy; Jigar Parikh | Zendy; Joyce Antal | Zendy; Xiaoping Jin | Zendy; Ashok Gupta | Zendy; Yong Ben | Zendy; Noah M. Hahn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

Author(s) -

Thomas Powles,

Peter H. O’Donnell,

Christophe Massard,

Hendrik-Tobias Arkenau,

Terence W. Friedlander,

Christopher Hoimes,

JaeLyun Lee,

Michael Ong,

Srikala S. Sridhar,

Nicholas J. Vogelzang,

Mayer Fishman,

Jingsong Zhang,

Sandy Srinivas,

Jigar Parikh,

Joyce Antal,

Xiaoping Jin,

Ashok Gupta,

Yong Ben,

Noah M. Hahn

Publication year - 2017

Publication title -

jama oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 8.846

H-Index - 99

eISSN - 2374-2445

pISSN - 2374-2437

DOI - 10.1001/jamaoncol.2017.2411

Subject(s) - medicine , durvalumab , metastatic urothelial carcinoma , response evaluation criteria in solid tumors , urothelial cancer , oncology , stage (stratigraphy) , cancer , chemotherapy , phases of clinical research , surgery , urology , bladder cancer , urothelial carcinoma , nivolumab , immunotherapy , paleontology , biology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research